查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1403521

介入性腫瘤學市場至2030年的預測：按產品、適應症、手術類型、最終用戶和地區的全球分析

Interventional Oncology Market Forecasts to 2030 - Global Analysis By Product (Ablation Devices, Embolization Devices and Support Devices), Indication, Procedure Type, End User and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3個工作天內

價格

根據Stratistics MRC預測，2023年全球介入性腫瘤市場規模將達24億美元，預計2030年將達到44億美元，預測期內年複合成長率為8.8%。

在介入放射學領域，介入性腫瘤學著重於使用微創方法進行癌症檢測和治療。在這些手術中，將使用透視、磁振造影（MRI）、電腦斷層掃描（CT）和超音波顯像模式來指導工具定位並直接針對惡性提供標靶治療。

根據美國癌症協會的資料，男性終生罹患乳癌的風險約為 833 分之一。因此，隨著乳癌負擔的增加，介入性腫瘤手術預計在預測期內會增加，這將推動市場成長。

對微創治療的需求不斷成長

由於患者和醫療保健專業人員對微創手術的需求不斷增加，介入性腫瘤治療的應用越來越廣泛。與開放性手術相比，這些方法具有更快的恢復時間，更短的住院時間和更少的併發症。因此，某些癌症類型的治療擴大轉向介入性腫瘤學方法。朝向以患者為中心的醫療轉變，即患者尋求恢復時間更短、副作用更少、生活品質更高的治療方法，這與推動市場成長的微創手術是一致的。

缺乏合格的實驗室技術人員

缺乏熟練的實驗室專業人員可能會危及所提供的護理品質。擁有必要技能的專業人員對於準確無誤地執行這些複雜的操作非常重要，而短缺可能會影響獲得最佳結果的可用知識水準。在技​​術人員短缺的地區和醫療機構，患者接觸腫瘤介入專家的機會可能有限。因此，患者接受微創癌症治療的能力可能會受到這些獲取差距的影響。

加大政府支持與償付政策

更好的償付指南和增加的政府支持可能會推動介入腫瘤治療市場的發展。希望改善的經濟獎勵和保險覆蓋範圍將鼓勵更多的提供者提供這些治療並改善患者的可及性。由於償付規定的改善，尋求介入癌症治療的患者可能面臨更少的財務障礙。這將確保更多的患者能夠獲得這些治療，更多的人能夠獲得尖端的微創癌症治療。

醫療設備嚴格監管

由於滿足嚴格的監管標準所需的大量測試、文件記錄和合規程序，開發用於介入腫瘤學的新醫療設備可能成本高昂。願意投資新技術研發的公司數量可能會因開發成本增加而受到阻礙。儘管這些法律的目的是保護患者，但它們也可能抑制新設備和技術進入市場，並可能延遲介入腫瘤治療的發展。

COVID-19 的影響

由於擔心在醫療環境中感染病毒，一些患者推遲了癌症治療，特別是介入治療，或完全尋求醫療協助。這種延遲可能妨礙了基本癌症治療的及時開始或持續。為了減少住院時間和病毒感染的風險，腫瘤學家和其他醫療保健專業人員可能改變了治療策略，傾向於全身藥物和其他治療方法而不是介入治療。

預計在預測期內消融設備市場將是最大的

由於消融設備為治療不同類型的腫瘤提供了一種侵入性較小的選擇，因此預計這些設備的市場將增加收益。這些設備使用熱、冷或其他能源來源來破壞腫瘤，而不是透過手術切除。這些消融裝置用於介入性腫瘤治療，例如安寧療護、腫瘤縮小和腫瘤切除。與傳統手術相比，它具有侵入性更小、恢復更快、併發症更少等優勢，使其成為一些癌症患者的首選，並推動了市場的發展。

骨癌領域預計在預測期內年複合成長率最高。

骨癌的傳統治療方法包括手術、化療，有時還包括放射線治療。然而，介入性腫瘤學治療方法在某些情況下或作為傳統癌症治療的補充可能有用。如果骨癌進展或引起問題，安寧療護可能包括介入治療。例如，介入性放射治療，例如腫瘤切除術（射頻消融或冷凍），用於治療疼痛或控制與骨轉移相關的症狀。

佔比最大的地區：

亞太地區報告了大量癌症病例，其中一些國家的發生率很高。該地區的癌症發生率受到許多變數的影響，包括生活方式的改變，環境的變化和加強的癌症篩檢計劃。此外，透過將尖端介入腫瘤學技術（包括 MRI、CT 和超音波等影像方式）與最先進的儀器和設備相結合，可以提高癌症治療的準確性、有效性和安全性。推動市場成長。

年複合成長率最高的地區：

在北美，市場受到完善的醫療系統、先進的技術開拓以及對微創癌症治療需求不斷成長的推動，因此預測期內的年複合成長率預計北美最高。此外，高癌症發病率、該地區完善的醫療保健系統、技術開拓以及對微創癌症治療日益成長的需求推動市場發展。

免費客製化服務

訂閱此報告的客戶可以存取以下免費自訂選項之一：

  • 公司簡介
    • 其他市場參與者的綜合分析（最多3家公司）
    • 主要企業SWOT分析（最多3家公司）
  • 區域細分
    • 根據客戶興趣對主要國家的市場估計、預測和年複合成長率（註：基於可行性檢查）
  • 競爭基準化分析
    • 根據產品系列、地理分佈和策略聯盟對主要企業基準化分析

目錄

第1章 執行摘要

第2章 前言

  • 概述
  • 相關利益者
  • 調查範圍
  • 調查方法
    • 資料探勘
    • 資料分析
    • 資料檢驗
    • 研究途徑
  • 調查來源
    • 主要調查來源
    • 二次調查來源
    • 先決條件

第3章 市場趨勢分析

  • 促進因素
  • 抑制因素
  • 機會
  • 威脅
  • 產品分析
  • 最終用戶分析
  • 新興市場
  • 新型冠狀病毒感染疾病（COVID-19）的影響

第4章 波特五力分析

  • 供應商的議價能力
  • 買方議價能力
  • 替代品的威脅
  • 新進入者的威脅
  • 競爭公司之間的敵對關係

第5章 全球介入腫瘤學市場：依產品

  • 消融裝置
    • 冷凍裝置
    • 微波消融裝置
    • 射頻（RF）消融裝置
    • 其他消融裝置
  • 栓塞裝置
    • 非放射性栓塞劑
      • 微球
      • 微粒
      • 塗層微球
      • 載藥微球
    • 放射性栓塞材料
  • 支撐裝置
    • 導管導引線
    • 微導管

第6章 全球介入腫瘤學市場：依適應症分類

  • 肝細胞癌
  • 骨癌
  • 腎癌
  • 肺癌
  • 神經內分泌腫瘤
  • 多形性膠質母細胞瘤
  • 脾腫大
  • 轉移性大腸直腸癌
  • 其他適應症

第7章 全球介入腫瘤學市場：依手術類型

  • 經導管動脈栓塞
  • 經導管動脈栓塞
  • 腫瘤熱消融術
  • 非熱腫瘤消融
  • 經導管動脈栓塞
  • 其他治療類型

第8章 全球介入腫瘤學市場：依最終用戶分類

  • 門診手術中心
  • 研究和學術機構
  • 醫院
  • 其他最終用戶

第9章 全球介入腫瘤學市場：依地區

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 義大利
    • 法國
    • 西班牙
    • 其他歐洲國家
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 紐西蘭
    • 韓國
    • 其他亞太地區
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 南美洲其他地區
  • 中東和非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 卡達
    • 南非
    • 其他中東和非洲

第10章 主要進展

  • 合約、夥伴關係、協作和合資企業
  • 收購和合併
  • 新產品發布
  • 業務擴展
  • 其他關鍵策略

第11章 公司簡介

  • AngioDynamics Inc.
  • Cook Medical
  • HealthTronics Inc.
  • Boston Scientific Corporation
  • Medtronic PLC
  • Terumo Corporation
  • Becton, Dickinson and Company
  • Merit Medical Systems Inc.
  • Profound Medical Corp.
  • IceCure Medical
  • Siemens Healthineers
  • Teleflex Incorporated
  • Medtronic Plc.
  • Alpinion Medical Systems Co.
  • IMBiotechnologies
  • Interface Biomaterials BV
  • Monteris Medical
  • Baylis Medical
  • Mermaid Medicals
  • Trod Medical
Product Code: SMRC24746

According to Stratistics MRC, the Global Interventional Oncology Market is accounted for $2.4 billion in 2023 and is expected to reach $4.4 billion by 2030 growing at a CAGR of 8.8% during the forecast period. Within the area of interventional radiology, interventional oncology focuses on the use of minimally invasive methods for the detection and treatment of cancer. During these operations, imaging modalities including fluoroscopy, magnetic resonance imaging (MRI), computed tomography (CT), and ultrasound are used to guide the positioning of tools and provide targeted therapies directly to malignancies.

According to the American Cancer Society, a man's lifetime risk of developing breast cancer is about 1 in 833. Hence, with the growing burden of breast cancer, interventional oncology procedures are expected to increase over the forecast period, which will drive growth in the market

Market Dynamics:

Driver:

Growing demand for minimally invasive therapeutics

Interventional oncology treatments are becoming more widely used as a result of patients' and healthcare professionals' growing demand for minimally invasive procedures. Compared to open operations, these methods provide quicker recovery periods, shorter hospital stays, and fewer problems. As a result, the treatment of some cancer types is increasingly moving toward interventional oncology techniques. The movement toward patient-centric care, in which patients look for therapies that provide shorter recovery periods, fewer side effects, and enhanced quality of life, is consistent with minimally invasive procedures which boost the market growth.

Restraint:

Lack of qualified laboratory personnel

The quality of care given might be jeopardized by a lack of skilled laboratory professionals. Professionals with the necessary skills are essential for carrying out these complex operations precisely and accurately, and a lack might impact the level of knowledge available to get the best results. Patients may have restricted access to specialist Interventional Oncology services in areas or healthcare settings where there is a shortage of skilled staff. Thus, the capacity of patients to get minimally invasive cancer therapies may be impacted by this gap in access.

Opportunity:

Increase in the government support and reimbursement policies

Better reimbursement guidelines and increased government assistance might propel the market for interventional oncology therapies forward. Better financial incentives and coverage are expected to encourage more healthcare providers to provide these therapies, increasing patient accessibility. Patients pursuing interventional cancer therapies may face less financial obstacles with improved reimbursement regulations. This may result in more patients having access to these treatments, guaranteeing that more people will have access to cutting-edge, minimally invasive cancer treatments.

Threat:

Stringent regulations for medical devices

Creating novel medical devices for interventional oncology may become quite expensive as a result of the considerable testing, paperwork, and compliance procedures needed to meet strict regulatory criteria. The number of businesses ready to invest in research and development for new technologies may be hampered by higher development expenses. Although the goal of these laws is to protect patients, they can also impede the introduction of novel devices and technologies into the market, which could postpone the development of interventional oncology therapies.

COVID-19 Impact

Fears of contracting the virus in medical settings caused some patients to postpone receiving cancer therapies, especially interventional procedures, or seeking medical assistance altogether. It's possible that this delay interfered with the timely start or continuation of essential cancer therapies. In order to reduce hospital stays or the risk of contracting the virus, oncologists and other healthcare professionals may have modified treatment strategies, preferring systemic medications or other forms of therapy over interventional procedures.

The ablation devices segment is expected to be the largest during the forecast period

Due to the fact that ablation devices provide less intrusive options for treating a variety of tumor types, the market for these devices is predicted to increase profitably. These devices destroy tumors by using heat, cold, or other energy sources instead of surgical excision. These ablation devices are used in palliative care, tumor reduction, and tumor ablation, among other interventional oncology therapies. Their advantages over traditional surgery, such as less invasiveness, faster recovery, and fewer complications, make them desirable options for some cancer patients and drive the market.

The osteosarcoma segment is expected to have the highest CAGR during the forecast period

The osteosarcoma segment is anticipated to witness the highest CAGR growth during the forecast period; surgery, chemotherapy, and sometimes radiation therapy are used in conjunction as the conventional treatment for osteosarcoma. Interventional oncology methods, however, could be useful in some situations or in addition to conventional cancer therapies. Palliative treatment may involve interventional therapies if the osteosarcoma has progressed or caused problems. To treat pain or control symptoms related to bone metastases, for example, interventional radiology procedures such as tumor ablation (radiofrequency or cryoablation) may be employed.

Region with largest share:

Asia Pacific is projected to hold the largest market share during the forecast period owing to A considerable number of cancer cases that are reported in Asia Pacific, with some of the region's nations having high incidence rates. The incidence of cancer in the area is influenced by a number of variables, including changes in lifestyle, alterations in the environment, and heightened cancer screening programs. Moreover the precision, effectiveness, and safety in cancer therapies are improved by the use of cutting-edge interventional oncology technology, including imaging modalities like MRI, CT, and ultrasound, in conjunction with cutting-edge instruments and equipment drives the growth of the market.

Region with highest CAGR:

North America is projected to have the highest CAGR over the forecast period, owing to the region's well-established healthcare system, technology developments, and the rising desire for minimally invasive cancer therapies are the main drivers of the market. Furthermore the high incidence of cancer, the region's well-established healthcare system, technology developments, and the rising desire for minimally invasive cancer therapies are the main drivers of the market.

Key players in the market:

Some of the key players profiled in the Interventional Oncology Market include AngioDynamics Inc., Cook Medical, HealthTronics Inc, Boston Scientific Corporation, Medtronic PLC, Terumo Corporation, Becton, Dickinson and Company, Merit Medical Systems Inc, Profound Medical Corp, IceCure Medical, Siemens Healthineers, Teleflex Incorporated, Medtronic Plc., Alpinion Medical Systems Co., IMBiotechnologies, Interface Biomaterials BV, Monteris Medical, Baylis Medical, Mermaid Medicals and Trod Medical

Key Developments:

In November 2023, Boston Scientific Corporation announced the close of its acquisition of Relievant Medsystems Inc., a company that offers the only U.S. Food and Drug Administration-cleared Intracept® Intraosseous Nerve Ablation System, a therapy to treat vertebrogenic pain that is a form of chronic low back pain.

In September 2023, Medtronic plc announced CE (Conformite Europeenne) Mark approval for its new all-in-one, disposable Simplera™ continuous glucose monitor (CGM) featuring a simple, two-step insertion process.

In July 2023, Purdue, IU and Cook Medical partner for 3-pronged approach to improve pediatric care. The Crossroads Pediatric Device Consortium will focus on meeting unmet needs for pediatric patients by accelerating the development, approval and availability of innovative medical devices for children.

Products Covered:

  • Ablation Devices
  • Embolization Devices
  • Support Devices

Indications Covered:

  • Hepatocellular Carcinoma
  • Osteosarcoma
  • Renal Cancer
  • Lung Cancer
  • Neuroendocrine Tumor
  • Glioblastoma Multiforme
  • Splenomegaly
  • Metastatic Colorectal Cancer
  • Other Indications

Procedure Types Covered:

  • Transcatheter Arterial Radioembolization
  • Transcatheter Arterial Chemoembolization
  • Thermal Tumor Ablation
  • Non-Thermal Tumor Ablation
  • Transcatheter Arterial Embolization
  • Other Procedure Types

End Users Covered:

  • Ambulatory Surgery Centers
  • Research & Academic Institutes
  • Hospitals
  • Other End Users

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Product Analysis
  • 3.7 End User Analysis
  • 3.8 Emerging Markets
  • 3.9 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Interventional Oncology Market, By Product

  • 5.1 Introduction
  • 5.2 Ablation Devices
    • 5.2.1 Cryoablation Devices
    • 5.2.2 Microwave Ablation Devices
    • 5.2.3 Radiofrequency (RF) Ablation Devices
    • 5.2.4 Other Ablation Devices
  • 5.3 Embolization Devices
    • 5.3.1 Non-Radio embolic Agents
      • 5.3.1.1 Microspheres
      • 5.3.1.2 Microparticles
      • 5.3.1.3 Coated Beads
      • 5.3.1.4 Drug Eluting Beads
    • 5.3.2 Radioembolic Agents
  • 5.4 Support Devices
    • 5.4.1 Guidewires
    • 5.4.2 Microcatheters

6 Global Interventional Oncology Market, By Indication

  • 6.1 Introduction
  • 6.2 Hepatocellular Carcinoma
  • 6.3 Osteosarcoma
  • 6.4 Renal Cancer
  • 6.5 Lung Cancer
  • 6.6 Neuroendocrine Tumor
  • 6.7 Glioblastoma Multiforme
  • 6.8 Splenomegaly
  • 6.9 Metastatic Colorectal Cancer
  • 6.10 Other Indications

7 Global Interventional Oncology Market, By Procedure Type

  • 7.1 Introduction
  • 7.2 Transcatheter Arterial Radioembolization
  • 7.3 Transcatheter Arterial Chemoembolization
  • 7.4 Thermal Tumor Ablation
  • 7.5 Non-Thermal Tumor Ablation
  • 7.6 Transcatheter Arterial Embolization
  • 7.7 Other Procedure Types

8 Global Interventional Oncology Market, By End User

  • 8.1 Introduction
  • 8.2 Ambulatory Surgery Centers
  • 8.3 Research & Academic Institutes
  • 8.4 Hospitals
  • 8.5 Other End Users

9 Global Interventional Oncology Market, By Geography

  • 9.1 Introduction
  • 9.2 North America
    • 9.2.1 US
    • 9.2.2 Canada
    • 9.2.3 Mexico
  • 9.3 Europe
    • 9.3.1 Germany
    • 9.3.2 UK
    • 9.3.3 Italy
    • 9.3.4 France
    • 9.3.5 Spain
    • 9.3.6 Rest of Europe
  • 9.4 Asia Pacific
    • 9.4.1 Japan
    • 9.4.2 China
    • 9.4.3 India
    • 9.4.4 Australia
    • 9.4.5 New Zealand
    • 9.4.6 South Korea
    • 9.4.7 Rest of Asia Pacific
  • 9.5 South America
    • 9.5.1 Argentina
    • 9.5.2 Brazil
    • 9.5.3 Chile
    • 9.5.4 Rest of South America
  • 9.6 Middle East & Africa
    • 9.6.1 Saudi Arabia
    • 9.6.2 UAE
    • 9.6.3 Qatar
    • 9.6.4 South Africa
    • 9.6.5 Rest of Middle East & Africa

10 Key Developments

  • 10.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 10.2 Acquisitions & Mergers
  • 10.3 New Product Launch
  • 10.4 Expansions
  • 10.5 Other Key Strategies

11 Company Profiling

  • 11.1 AngioDynamics Inc.
  • 11.2 Cook Medical
  • 11.3 HealthTronics Inc.
  • 11.4 Boston Scientific Corporation
  • 11.5 Medtronic PLC
  • 11.6 Terumo Corporation
  • 11.7 Becton, Dickinson and Company
  • 11.8 Merit Medical Systems Inc.
  • 11.9 Profound Medical Corp.
  • 11.10 IceCure Medical
  • 11.11 Siemens Healthineers
  • 11.12 Teleflex Incorporated
  • 11.13 Medtronic Plc.
  • 11.14 Alpinion Medical Systems Co.
  • 11.15 IMBiotechnologies
  • 11.16 Interface Biomaterials BV
  • 11.17 Monteris Medical
  • 11.18 Baylis Medical
  • 11.19 Mermaid Medicals
  • 11.20 Trod Medical

List of Tables

  • Table 1 Global Interventional Oncology Market Outlook, By Region (2021-2030) ($MN)
  • Table 2 Global Interventional Oncology Market Outlook, By Product (2021-2030) ($MN)
  • Table 3 Global Interventional Oncology Market Outlook, By Ablation Devices (2021-2030) ($MN)
  • Table 4 Global Interventional Oncology Market Outlook, By Cryoablation Devices (2021-2030) ($MN)
  • Table 5 Global Interventional Oncology Market Outlook, By Microwave Ablation Devices (2021-2030) ($MN)
  • Table 6 Global Interventional Oncology Market Outlook, By Radiofrequency (RF) Ablation Devices (2021-2030) ($MN)
  • Table 7 Global Interventional Oncology Market Outlook, By Other Ablation Devices (2021-2030) ($MN)
  • Table 8 Global Interventional Oncology Market Outlook, By Embolization Devices (2021-2030) ($MN)
  • Table 9 Global Interventional Oncology Market Outlook, By Non-Radio embolic Agents (2021-2030) ($MN)
  • Table 10 Global Interventional Oncology Market Outlook, By Microspheres (2021-2030) ($MN)
  • Table 11 Global Interventional Oncology Market Outlook, By Microparticles (2021-2030) ($MN)
  • Table 12 Global Interventional Oncology Market Outlook, By Coated Beads (2021-2030) ($MN)
  • Table 13 Global Interventional Oncology Market Outlook, By Drug Eluting Beads (2021-2030) ($MN)
  • Table 14 Global Interventional Oncology Market Outlook, By Radioembolic Agents (2021-2030) ($MN)
  • Table 15 Global Interventional Oncology Market Outlook, By Support Devices (2021-2030) ($MN)
  • Table 16 Global Interventional Oncology Market Outlook, By Guidewires (2021-2030) ($MN)
  • Table 17 Global Interventional Oncology Market Outlook, By Microcatheters (2021-2030) ($MN)
  • Table 18 Global Interventional Oncology Market Outlook, By Indication (2021-2030) ($MN)
  • Table 19 Global Interventional Oncology Market Outlook, By Hepatocellular Carcinoma (2021-2030) ($MN)
  • Table 20 Global Interventional Oncology Market Outlook, By Osteosarcoma (2021-2030) ($MN)
  • Table 21 Global Interventional Oncology Market Outlook, By Renal Cancer (2021-2030) ($MN)
  • Table 22 Global Interventional Oncology Market Outlook, By Lung Cancer (2021-2030) ($MN)
  • Table 23 Global Interventional Oncology Market Outlook, By Neuroendocrine Tumor (2021-2030) ($MN)
  • Table 24 Global Interventional Oncology Market Outlook, By Glioblastoma Multiforme (2021-2030) ($MN)
  • Table 25 Global Interventional Oncology Market Outlook, By Splenomegaly (2021-2030) ($MN)
  • Table 26 Global Interventional Oncology Market Outlook, By Metastatic Colorectal Cancer (2021-2030) ($MN)
  • Table 27 Global Interventional Oncology Market Outlook, By Other Indications (2021-2030) ($MN)
  • Table 28 Global Interventional Oncology Market Outlook, By Procedure Type (2021-2030) ($MN)
  • Table 29 Global Interventional Oncology Market Outlook, By Transcatheter Arterial Radioembolization (2021-2030) ($MN)
  • Table 30 Global Interventional Oncology Market Outlook, By Transcatheter Arterial Chemoembolization (2021-2030) ($MN)
  • Table 31 Global Interventional Oncology Market Outlook, By Thermal Tumor Ablation (2021-2030) ($MN)
  • Table 32 Global Interventional Oncology Market Outlook, By Non-Thermal Tumor Ablation (2021-2030) ($MN)
  • Table 33 Global Interventional Oncology Market Outlook, By Transcatheter Arterial Embolization (2021-2030) ($MN)
  • Table 34 Global Interventional Oncology Market Outlook, By Other Procedure Types (2021-2030) ($MN)
  • Table 35 Global Interventional Oncology Market Outlook, By End User (2021-2030) ($MN)
  • Table 36 Global Interventional Oncology Market Outlook, By Ambulatory Surgery Centers (2021-2030) ($MN)
  • Table 37 Global Interventional Oncology Market Outlook, By Research & Academic Institutes (2021-2030) ($MN)
  • Table 38 Global Interventional Oncology Market Outlook, By Hospitals (2021-2030) ($MN)
  • Table 39 Global Interventional Oncology Market Outlook, By Other End Users (2021-2030) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.